Literature DB >> 7771542

Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor.

L Liu1, K B Pasumarthi, R R Padua, H Massaeli, R R Fandrich, G N Pierce, P A Cattini, E Kardami.   

Abstract

As a first step in addressing the question of function for basic fibroblast growth factor (bFGF) in the adult myocardium, expression of bFGF receptors by adult rat myocytes was investigated. Cross-linking of 125I-labeled bFGF to purified sarcolemmal vesicles from adult hearts indicated specific binding to 90- to 104-kDa proteins, whereas equilibrium binding studies revealed the presence of "low"-affinity (1 nM) and "high"-affinity (115 pM) sites. Adult myocytes were found to express short and long variants of bFGF receptor 1 (FGFR-1, tyrosine kinase) mRNA. Adult heart overall levels of FGFR-1 mRNA were decreased by about one-third of corresponding fetal values. Several lines of evidence indicated that bFGF receptors in adult cardiomyocytes in situ and/or in isolation are functional. Isolated adult myocytes were found to be capable of heparin-resistant internalization of 125I-labeled bFGF, to lose their viability after interaction with bFGF-saporin (a mitotoxin known to kill cells after entry via the bFGF receptor), and to respond to bFGF by activation of mitogen-activated protein kinase. In addition, introduction of exogenous bFGF into the myocardium by Langendorff perfusion resulted in stimulation of tyrosine phosphorylation in association with cardiomyocyte intercalated disks, as assessed by immunofluorescence. It is concluded that adult cardiomyocytes express functionally coupled high-affinity bFGF receptors and that they are capable of a biologic response to bFGF in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7771542     DOI: 10.1152/ajpheart.1995.268.5.H1927

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

1.  Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.

Authors:  Stacey L House; Brian E House; Betty Glascock; Thomas Kimball; Eyad Nusayr; Jo El J Schultz; Thomas Doetschman
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.

Authors:  J E Schultz; S A Witt; M L Nieman; P J Reiser; S J Engle; M Zhou; S A Pawlowski; J N Lorenz; T R Kimball; T Doetschman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury.

Authors:  Siyun Liao; Janet R Bodmer; Mohamad Azhar; Gilbert Newman; J Douglas Coffin; Thomas Doetschman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2010-01-29       Impact factor: 5.000

4.  Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.

Authors:  Wacharee Seeherunvong; Carolyn L Abitbol; Jayanthi Chandar; Paolo Rusconi; Gaston E Zilleruelo; Michael Freundlich
Journal:  Pediatr Nephrol       Date:  2012-06-19       Impact factor: 3.714

5.  Expression of fibroblast growth factor receptor-1 in rat heart H9c2 myoblasts increases cell proliferation.

Authors:  F Sheikh; Y Jin; K B Pasumarthi; E Kardami; P A Cattini
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

6.  Involvement of tyrosine phosphorylation in the positive inotropic effect produced by H(1)-receptors with histamine in guinea-pig left atrium.

Authors:  Y Akaishi; Y Hattori; K Yoshimoto; A Kitabatake; K Yasuda; M Kanno
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

7.  FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development.

Authors:  Shun Yan Lu; David P Sontag; Karen A Detillieux; Peter A Cattini
Journal:  Am J Physiol Cell Physiol       Date:  2008-03-12       Impact factor: 4.249

8.  Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Authors:  Jacob A Udell; David A Morrow; Petr Jarolim; Sarah Sloan; Elaine B Hoffman; Thomas F O'Donnell; Amit N Vora; Torbjørn Omland; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2014-04-09       Impact factor: 24.094

Review 9.  Fibroblast growth factor-2 and cardioprotection.

Authors:  Elissavet Kardami; Karen Detillieux; Xin Ma; Zhisheng Jiang; Jon-Jon Santiago; Sarah K Jimenez; Peter A Cattini
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.